Centiva Capital’s Ascendis Pharma A/S ASND Stock Holding History

Centiva Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-220	Closed	-$19.1K	–	1619
2023 Q1	$23.6K	Sell	220 -968	-81%	-$111K	﹤0.01%	1422
2022 Q4	$145K	Buy	+1,188	New	+$138K	﹤0.01%	1137
2022 Q1	–	Sell	-1,640	Closed	-$221K	–	1606
2021 Q4	$221K	Buy	+1,640	New	+$244K	﹤0.01%	976

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Centiva Capital's ASND Position: Q2 2023 in Review

Centiva Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2023, closing a stake of 220 shares — an estimated $19.1K sold.

Centiva Capital first reported a position in ASND in Q4 2021 and held it in 3 quarters. The position peaked at $221K in Q4 2021. 157 funds tracked by Wall St. Rank hold ASND as of Q2 2023.

Centiva Capital reported no remaining Ascendis Pharma A/S position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 220 Ascendis Pharma A/S shares in Q2 2023, an estimated $19.1K.
Centiva Capital first reported a position in Ascendis Pharma A/S in Q4 2021 and held it in 3 quarters.
Centiva Capital's Ascendis Pharma A/S position peaked at $221K in Q4 2021.
157 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.